ANGIOTENSIN CONVERTING ENZYME-INHIBITION IN PATIENTS WITH CONGESTIVE HEART-FAILURE
ANGIOTENSIN CONVERTING ENZYME-INHIBITION IN PATIENTS WITH CONGESTIVE HEART-FAILURE
复制标题
DOI：
10.1161/01.cir.58.5.770
复制
发表时间：
1978-01-01
期刊：
影响因子：
37.8
通讯作者：
RYAN, TJ
中科院分区：
文献类型：
--
作者：
GAVRAS, H;FAXON, DP;RYAN, TJ
充血性心力衰竭后负荷升高的病因尚不清楚，但实验证据表明，肾素-血管紧张素系统在维持外周血管阻力升高中发挥作用。8例充血性心力衰竭患者（4例高血压患者，4例血压正常者）在诊断性心导管插入术期间或术后1天给予血管紧张素转换酶抑制剂SQ 20，881（替普罗肽）。在阻滞前和阻滞期间进行的各种血流动力学测量表明，该药物通过降低后负荷改善了所有患者的心脏功能。这种改善与总血管阻力的降低相关，但与基线血压和血浆肾素活性无关。抑制血管紧张素转换酶是治疗充血性心力衰竭的一种有价值的方法，但其确切的作用机制尚不清楚。
The etiology of afterload elevation in congestive cardiac failure is unclear, but experimental evidence suggests a role for the renin-angiotensin system in maintaining elevated peripheral vascular resistance. The angiotensin converting enzyme inhibitor SQ20,881 (teprotide) was administered to 8 patients with congestive cardiac failure (4 hypertensives, 4 normotensives) during or 1 day after diagnostic cardiac catheterization. Various hemodynamic measurements performed before and during blockade indicate that this agent caused improvement in cardiac function in all patients by decreasing afterload. This improvement correlated with the decrease in total vascular resistance but was independent of the baseline blood pressure and plasma renin activity. Inhibition of angiotensin converting enzyme is a worthwhile approach to the treatment of congestive heart failure, although its exact mechanism of action remains unclear.